Stay updated with breaking news from Final Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...
Itolizumab was associated with high clinical response rates at Day 15 and 29Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif.--(BUSINESS WIRE)--$EQ #GVHD--Equillium, Inc...
Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY (diroximel fumarate) consistent with previous
/PRNewswire/ -- Neurelis, Inc., today announced findings from a novel, investigational analysis of the time between seizure clusters in pediatric patients...
/PRNewswire/ -- Neurelis, Inc., today announced findings from a novel, investigational analysis of the time between seizure clusters in pediatric patients...